RadNet (NASDAQ:RDNT) is set to release its earnings data before the market opens on Friday, November 9th. Analysts expect RadNet to post earnings of $0.15 per share for the quarter.
RadNet (NASDAQ:RDNT) last posted its quarterly earnings data on Thursday, August 9th. The medical research company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). RadNet had a positive return on equity of 17.00% and a negative net margin of 0.64%. The firm had revenue of $244.40 million during the quarter, compared to analyst estimates of $239.34 million. During the same period in the prior year, the business posted $0.11 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, analysts expect RadNet to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
RadNet stock opened at $14.55 on Wednesday. RadNet has a 52 week low of $9.50 and a 52 week high of $16.54. The company has a debt-to-equity ratio of 4.49, a current ratio of 1.06 and a quick ratio of 1.06. The company has a market capitalization of $707.37 million, a P/E ratio of 50.17, a PEG ratio of 5.16 and a beta of 0.36.
In other RadNet news, insider Norman R. Hames sold 14,000 shares of the stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $15.59, for a total value of $218,260.00. Following the completion of the sale, the insider now owns 589,000 shares in the company, valued at approximately $9,182,510. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jeffrey L. Linden sold 10,000 shares of the stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $14.78, for a total transaction of $147,800.00. Following the completion of the sale, the insider now owns 902,001 shares of the company’s stock, valued at approximately $13,331,574.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,000 shares of company stock valued at $506,660. Insiders own 7.56% of the company’s stock.
A hedge fund recently raised its stake in RadNet stock. Bank of New York Mellon Corp boosted its stake in RadNet Inc. (NASDAQ:RDNT) by 3.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 185,216 shares of the medical research company’s stock after buying an additional 6,054 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.38% of RadNet worth $2,778,000 at the end of the most recent quarter. 61.21% of the stock is owned by institutional investors.
A number of research firms recently commented on RDNT. BidaskClub lowered shares of RadNet from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Zacks Investment Research raised shares of RadNet from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Wednesday, October 10th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $15.50.
ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/07/radnet-rdnt-set-to-announce-earnings-on-friday.html.
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
Read More: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.